

**How to Cite:**

Ramandeep, K., Jasveer, K., Gurpreet, K., Ritika, S., Chamanpreet, K., & Sandeep, K. (2022). An updated overview: Drug carriers used for the targeted delivery system. *International Journal of Health Sciences*, 6(S5), 4610–4618. <https://doi.org/10.53730/ijhs.v6nS5.10090>

## **An updated overview: Drug carriers used for the targeted delivery system**

**Kaur Ramandeep**

Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (Ropar) 140111, Punjab, India.

Corresponding author email: [raman1604503017@gmail.com](mailto:raman1604503017@gmail.com)

**Kaur Jasveer**

Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (Ropar) 140111, Punjab, India.

**Kaur Gurpreet**

Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (Ropar) 140111, Punjab, India.

**Saini Ritika**

Department of Pharmaceutics, Laurette Institute of Pharmacy Kathog Jawalamukhi Distt.Kangra-176031

**Kaur Chamanpreet**

Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (Ropar) 140111, Punjab, India.

**Kumar Sandeep**

Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (Ropar) 140111, Punjab, India.

**Abstract**---In this high-tech era, the targeted drug delivery system has various progressions in the delivery of cancerous drugs. In the current review, the main purpose is to address the valuable needs of a targeted drug delivery system in all aspects of the safety and therapeutic delivery of drugs. The main objective is to introduce the drug carriers with their benefits. The targeted drug delivery system is superior to the traditional drug delivery system because they overcome the pros and cons and deliver the dosage form at the targeted site without exhibiting any side effects. The positive benefit of this system is that they reduce the dose dumping and provides the optimized delivery of drugs. The current review article elaborates on the different drug carriers used in the targeted drug delivery system such as liposomes, microspheres, and nanoparticles with their

importance, merits, and demerits. This article mainly concentrates on the applications and some other important facts related to the targeted drug delivery carriers.

**Keywords**--Chemotherapeutic drugs, Targeted drug delivery system, Conventional drug delivery system, Drug carriers, Site-specific action, Nano-carriers.

## **Introduction**

A targeted drug delivery system shows the advantages over the conventional delivery of drugs in terms of efficacious treatment with improved bioavailability and absorption status. This system works in the interest of the system i.e., the active moiety directly targets the specific tissue without affecting the other body tissues. This novel delivery system gain more attention in today's pharmaceuticals leading the world in all terms of its positive benefits with cost-effective treatment. Prevention, cure, and treatment are the main needs of human mankind and this is fulfilled by the high conversion technique known as the " Targeted drug delivery system".<sup>[1-3]</sup> Furthermore, this unique technology also controls the absorption, distribution, metabolism, and excretion parameters with improved bioavailability. This modernized and new technology works on the four principle guidelines and these are:

1. Loading of the drug to the specific site.
2. Avoids the first-pass metabolism and degradation of the drug.
3. Transferring the drug to the target site.
4. Release of a drug to the specific site at a predetermined rate.

In drug targeting, the drug is delivered to the capillaries of a specific site, specific cells like in the case of cancerous cells, or the special cells which easily recognize the drug carriers.<sup>[4-5]</sup>

### **Need of using the targeted drug delivery system-<sup>[6-7]</sup>**

Conventional formulations exhibit the various drawbacks like:

1. They exhibit lower drug solubility.
2. They possess a lower specificity to the tissue of interest.
3. They exhibit poor solubility and bioavailability characteristics.
4. They possess a narrow therapeutic window with a short half-life.
5. A large amount of drug is bounded in other body tissues.

### **Good characteristics and features of targeted drug delivery system-<sup>[8-9]</sup>**

1. They are non-toxic, non-allergic, and stable with other body fluid components.
2. They are highly compatible, safe, and stable dosage forms.
3. They deliver the drugs at a specific site with a predetermined release.
4. The procedure of manufacturing is uncomplicated and straightforward.
5. The release rate of drug delivery does not affect the ADME of the drug.
6. No leakage takes place during the transportation of drugs.

**Different types of Carriers explored in drug targeting-[10-11]**

Various kinds of drug carriers are used for the targeting delivery of drugs and they are listed as:

1. Liposomes which are also known as vesicles of lipids.
2. Niosomes which are known by vesicles of surfactants.
3. Ufasomes which are also called vesicles of unsaturated fatty acids.
4. Pharmacosomes
5. Virosomes
6. Transferosomes
7. Cubosomes
8. Nanobots
9. Nanocrystals
10. Hydrogels
11. Exosomes
12. Quantum dots
13. Gold nanoparticles
14. Dendrimers
15. Microsponges
16. Nanoferosponges

**1. Liposomes**

They exhibit a spherical shape and these are mainly formed by two layers of phospholipids. The lipid bilayer consists of an aqueous core that is covered by the neighboring lipid layer. This bilayer enables the liposomes to intermingle both the hydrophilic and lipophilic drugs. They have very high specificity to target the tumor tissues because they give good steady formulations. They are generally formulated by an artificial method by using the phospholipids in the aqueous solutions. Moreover, they are better used in the delivery of biotechnology products and also explored in treating parasitic infections.<sup>[12-15]</sup>

**2. Niosomes**

These are the vesicles of non-ionic surfactants which mainly consist of cholesterol and its alternatives. Their spherical structure allows to entrapped the hydrophilic and lipophilic drugs. This technology is one of the innovative and versatile systems which provides sustained release with a low therapeutic index. They act as drug carriers as a diagnostic agent and are also used as penetration enhancers. This new technology provides the potential delivery for various routes of administration.<sup>[16-19]</sup>

**3. Ufasomes**

Ufasomes is one of the vesicular drug delivery systems which are composed of unsaturated fatty acids and their ionized species. They are considered a good candidate for the delivery of topical drugs because the outermost layer penetration barrier is overcome by them due to the composition of lipid layers. They are more advantageous over the liposomes in case of stability and they are cost-effective as compared to the liposomes.<sup>[20-23]</sup>

**4. Pharmacosomes**

These are known as neutral molecules which consist of both the positive and negative charges. They are mainly complexation of polyphenol with phospholipids.

The word pharmacosomes means drug carrier and their conjugation with lipids gives the result of micelles formation. They have a high level of stability range. Furthermore, in the future, this technology is highly emerging in the case of synthetic and natural active pharmaceutical constituents.<sup>[24-25]</sup>

### **5. Virosomes**

This technology is a highly emerging novel carrier that can add to vaccines or as vehicles for different synthesis. They are prepared in combination with various agents for instance antigens, drugs, and viral cover proteins. They are mainly explored in the field of immunopotentiating agents.<sup>[26-28]</sup>

### **6. Transferosomes**

Transferosomes is one of the types of liposomes which generally carries phosphatidylcholine with an edge activator. They exhibit a highly distorted structure with greater penetration power. They have high payload entrapment efficiency. Due to the encapsulation layering, the metabolic degradation of drugs gets to be protected. The transferosomes have various utilizations in the delivery of anti-cancer drugs, analgesics, anti-fungal drugs anesthetics, and corticosteroids.<sup>[29-31]</sup>

### **7. Cubosomes**

These are made by lipids so they are known as nanostructured lipid carriers. These are highly versatile carriers that mainly plays important role in the treatment of cancer therapy and the drug explored in it are Doxorubicin, Cisplatin, Paclitaxel, Irinotecan, Curcumin, etc. These are made up of liquid crystalline nanoparticles which exhibit a cubic structure that is satisfactory for injection. Tween 80 is used as a stabilizer in it.<sup>[32-33]</sup>

### **8. Nanobots**

Nanobots is the branch of nanomedicine that is also known as a micro-scale delivery system. They are very small in vision so they can easily traverse the human body. They have a broad range of applications in dentistry, nanoimpression, in the diagnosis of cancer and diabetes. Nowadays, they are also used in gene therapy with improved better therapy.<sup>[34-36]</sup>

### **9. Nanocrystals**

Nanocrystals are one of the parts of nanotechnology and they exhibit structure like crystals. The main ingredient of the formulation is the drug and no carrier is needed for their formulations. Dispersion of aqueous medium results in the formation of nanosuspension. Nanocrystals improve the saturation solubility rate and dissolution velocity rate of poorly soluble drugs. Nanocrystals are different from nanoparticles in the dimensions because nanocrystals lie in the size range of less than 100nm whereas nanoparticle exhibits the dimensions of less than 1000nm.<sup>[37-39]</sup>

### **10. Hydrogels**

They exhibit a three-dimensional structure and hydrophilic structure enables them to hold a large amount of aqueous phase. Mechanisms included for the preparation of hydrogel are diffusion-controlled, swelling controlled, and

chemically controlled. It has a broad range of applications in the healing of wounds, tissue engineering studies, and delivery of drugs to the GI tract.<sup>[40-41]</sup>

### **11. Exosomes**

They exhibit the diameter range of 40-100 nm. Exosomes are bilayer vesicles of lipid. They are utilized in the diagnosis of disease by exhibiting the characteristics of a targeted drug delivery system.<sup>[42-44]</sup>

### **12. Quantum dots**

Quantum dots are nanocrystalline semiconductor carriers that can mainly be explored in the area of tumor targeting with improved bioavailability of drugs. They are well used for optical applications because they exhibit a high level of extinction value.<sup>[45-46]</sup>

### **13. Gold nanoparticles**

They exist in the form of protein markers and develop the supersensitive DNA molecule. They are mainly used in the biomedical field with advanced applications in the coverage area of bio-imaging. They are specifically manufactured for the targeting of the specific tissue without any interest in the other organ. Gold nanoparticles are used for the detection of different types of cancerous cells like breast cancer, lung cancer, and prostate cancer.<sup>[47-50]</sup>

### **14. Dendrimers**

These are generated by using synthetic nano-range particles with a specific diameter. Dendrimers are mainly composed of the central core which is further covered by the different types of polymers. This central core helps to improve the solubility of BCS-class 2 drugs. They are mainly explored in the area of medical imaging, delivery of antineoplastic drugs, and as well as in the therapy of genes.<sup>[51-54]</sup>

### **15. Microsponges**

Microsponge is a highly patented and cross-linked automation having a sponge-like preserved spherical structure along with a large porous surface. It provides novel and controlled pharmaceutical products. Another term used for microsponge is the "polymeric microspheres" and "solid-phase porous microbeads". They are very small in vision and the particle size ranges from 5 to 300 microns. Apart from it, they provide many benefits over the conventional products, nanocarrier, and microcarrier formulations in terms of stability, safety, bioavailability, and exhibit better drug performance parameters with lesser adverse effects.<sup>[55-58]</sup>

### **16. Nanoferrosponges**

These are the nano-carriers composed of the ferric ions and they are mainly activated by the help of the magnet. Nanoferrosponges have highly improved penetration power because of the external magnetism due to this the drug directly targets the specific tissue. It is also known as one of the new best approaches to a targeted drug delivery system.<sup>[59-61]</sup>

## Conclusions and prospects

Drug carriers are the forthcoming and highly modern technology that is used in the targeting of specific tissues with lesser adverse reactions. The targeted drug delivery system has more progressions with advantages in the area of all the above-listed drug carriers. These drug carriers provide superior benefits over conventional drug preparations. In the future, these drug carriers provides more benefits with the modification of micro and nanotechnology.

## References

1. Kumar A, Nautiyal U, Kaur C, Goel V, Piarchand N. Targeted drug delivery system: current and novel approach. *Int J Pharm Med Res.* 2017;5(2):448–454.
2. Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. *J Control Release.* 2012;164:108–114. doi:10.1016/j.jconrel.2012.07.010.
3. Gujral SS., Khatri S., A review on basic concept of drug targeting and drug carrier system, *IJAPBC* 2013;2:1.
4. Muller RH., Keck CM., Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles, *Journal of Biotechnology* 2004;113:1–3:151-170.
5. Vyas SP., Khar RK., Basis of targeted Drug Delivery. In *Targeted and controlled Drug Delivery*, CBS Publishers and Distributors Reprint 2008:42-46:74.
6. Jain NK., *Controlled and Novel Drug Delivery*, CBS publication, New delhi, 1st edition reprint 2008;100- 130,147-170, 304-352.
7. Vyas and Khar., *Targeted and Controlled drug delivery* (CBS Publishers and distributors 2001.
8. Mills JK, Needham D. Targeted drug delivery. *Expert Opin Ther Pat.* 1999;9(11):1499-513.
9. Torchilin VP. Drug targeting. *Eur J Pharm Sci.* 2000;11:S81-91.
10. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. *J Controlled Release.* 2011;153(3):198.
11. Mills JK, Needham D. Targeted drug delivery. *Expert Opin Ther Pat.* 1999;9(11):1499-513.
12. Chrai SS, Murari R, Imran A: Liposomes: a review. *Bio Pharm* 2001, 14(11):10–14.
13. Himanshu A, Sitasharan P, Singhai AK: Liposomes as drug carriers. *IJPLS* 2011, 2(7):945–951.
14. Kataria S, Sandhu P, Bilandi A, Akanksha M, Kapoor B, Seth GL, Bihani SD: Stealth liposomes: a review. *IJRAP* 2011, 2(5):1534–1538.
15. Hamilton RL, Guo LSS: Liposomes preparation methods. *J Clin Biochem Nut* 1984, 7: 175.
16. Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: Novel sustained release nonionic stable vesicular systems—an overview. *Adv Colloid Interface Sci.* 2012;183:46-54.
17. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: An illustrated review. *J Controlled Release.* 2014;185:22-36.

18. Pravinagurjar N, Chouksey S. Niosome: A promising pharmaceutical drug delivery. *Int J Pharm Drug Anal.* 2014;2:425-31.
19. Hargreaves WR, Deamer DW. Liposomes from ionic, single-chain amphiphiles. *Biochemistry* 1978;17:3759-68.
20. Patel DM, Jani RH, Patel CN. Ufasomes: A Vesicular Drug Delivery. *Systematic Reviews in Pharmacy.* 2011; 2(2): 72-78.
21. George A, Nair SC. Ufasome: A potential phospholipid as a novel pharmaceutical formulation. *Int. Res. J. Pharm.* 2014. 5(4): 250- 253.
22. Jain S, Mahajan SC. Lipid based vesicular drug delivery system. *Advances in Pharmaceutics.* 2014: 1-12.
23. Patel SA. Review on ufasomes and vesicular drug delivery system. *The Pharma Research.* 2013; 9(01): 32-43..
24. Semalty A, Semalty M, Rawat BS, Singh D, Rawat MSM. Pharmacosomes: The lipid-based new drug delivery system. *Expert Opin Drug Deliv.* 2009;6(6):599-612.
25. Semalty A, Semalty M, Rawat BS, Singh D, Rawat MSM. Development and evaluation of pharmacosomes of aceclofenac. *Indian J Pharm Sci.* 2010;72(5):576.
26. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosome concept for influenza vaccines. *Vaccine.* 2005;23:S26-38.
27. Cusi MG. Applications of influenza virosomes as a delivery system. *Hum Vaccin.* 2006;2(1):1-7.
28. Agnihotri J, Saraf S, Khale A. Targeting: New potential carriers for targeted drug delivery system. *Int J Pharm Sci Rev Res.* 2011;8(2):117-123.
29. Chaurasiya P., Ganju E., Upmanyu N., Ray S.K., Jain P. Transfersomes: A novel technique for transdermal drug delivery. *J. Drug Deliv. Ther.* 2019;9:279-285. doi: 10.22270/jddt.v9i1.2198.
30. Modi C., Bharadia P. Transfersomes: New dominants for transdermal drug delivery. *Am. J. PharmTech. Res.* 2012;2:71-91.
31. Jain A.K., Kumar F. Transfersomes: Ultradeformable vesicles for transdermal drug delivery. *Asian J. Biomater. Res.* 2017;3:1-13.
32. Garg G, Saraf S, Saraf S. Cubosomes: An overview. *Biol Pharm Bull.* 2007;30(2):350-3.
33. Azhari H, Strauss M, Hook S, Boyd BJ, Rizwan SB. Stabilising cubosomes with Tween 80 as a step towards targeting lipid nanocarriers to the blood-brain barrier. *Eur J Pharm Biopharm.* 2016;104:148-55.
34. Mali S. Nanorobots: Changing face of healthcare system. *Austin J Biomed Eng.* 2014;1(3):3.
35. Thangavel K, Balamurugan A, Elango M, Subiramaniam P, Senrayan M. A survey on nano-robotics in nano-medicine. *Nanotechnology.* 2014;8:9.
36. Andhari SS, Wavhale RD, Dhobale KD, Tawade BV, Chate GP, Patil YN, et al. Self-propelling targeted Magneto-nanobots for Deep tumor penetration and pH-Responsive intracellular Drug Delivery. *Sci Rep.* 2020;10(1):1-16.
37. Suryanarayana C, Froes FH. The structure and mechanical properties of metallic nanocrystals. *Metall Trans A.* 1992;23(4):1071-81.
38. Elazzouzi-Hafraoui S, Nishiyama Y, Putaux JL, Heux L, Dubreuil F, Rochas C. The shape and size distribution of crystalline nanoparticles prepared by acid hydrolysis of native cellulose. *Biomacromolecules.* 2008;9(1):57-65.

39. Liu F, Park JY, Zhang Y, Conwell C, Liu Y, Bathula SR, et al. Targeted cancer therapy with novel high drug-loading nanocrystals. *J Pharm Sci.* 2010;99(8):3542-551.
40. K. Pal, A. K. Banthia, and D. K. Majumdar, —Preparation and characterization of polyvinyl alcohol-gelatin hydrogel membranes for biomedical applications, *AAPS PharmSciTech*, 2007; 8: 1.
41. T. R. Hoare and D. S. Kohane, "Hydrogels in drug delivery: Progress and challenges," *Polymer*, 2008; 49(8): 1993–2007.
42. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. *Expert Rev Proteom.* 2009;6(3):267– 83. <https://doi.org/10.1586/epr.09.17>.
43. Kanaparthi R, Kanaparthi A. The changing face of dentistry: Nanotechnology. *Int J Nanomedicine.* 2011;6:2799.
44. Nagda D, Rathore KS, Bharkatiya M, Sisodia SS, Nema RK. Bucky balls: A novel drug delivery system. *J Chem Pharm RES.* 2010;2:240-3.
45. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. *Nat Biotechnol.* 2004;22(8):969-76.
46. Pardo J, Peng Z, Leblanc RM. Cancer targeting and drug delivery using carbon-based quantum dots and nanotubes. *Molecules.* 2018;23(2):378.
47. Thaxton CS, Georganopoulou DG, Mirkin CA. Gold nanoparticle probes for the detection of nucleic acid targets. *Clin Chim Acta.* 2006;363(1-2):120-6.
48. Huang X, O'Connor R, Kwizera EA. Gold nanoparticle based platforms for circulating cancer marker detection. *Nanotheranostics.* 2017;1(1):80.
49. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. *Lancet Oncol.* 2006;7(8):657-67.
50. Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. *Nat Nanotechnol.* 2009;4(10):669-73.
51. Rakhmonov, O. M., Shadmanov, A. K., & Juraev, F. M. (2021). Results of endoscopic treatment of benign prostatic hyperplasia in patients with metabolic syndrome. *International Journal of Health & Medical Sciences*, 5(1), 21-25. <https://doi.org/10.21744/ijhms.v5n1.1811>
52. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: Emerging polymers for drug-delivery systems. *Eur J Pharm Sci.* 2009;38(3):185-96.
53. Garg T, Singh O, Arora S, Murthy R. Dendrimer: A novel scaffold for drug delivery. *Int J Pharm Sci Rev Res.* 2011;7(2):211-20.
54. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. *Adv Drug Deliv Rev.* 2012;64:102-15.
55. Balogh L, Bielinska A, Eichman JD, Valluzzi R, Lee I, Baker JR, et al. Dendrimer nanocomposites in medicine. *Chim Oggi.* 2002;20(5):35-40.
56. Shinkar, DM, Bhamare, BS, Saudagar, RB. Microsponges. *Asian Journal of Research in Pharmaceutical Sciences* 2016;6(2):2231- 59.
57. Chowdary, KP, R, Rao, SY. Mucoadhesive microspheres for controlled drug delivery. *Biological and Pharmaceutical Bulletin* 2004;27(11):1717–24.
58. Chadawar, V, Shaji, J. Microsponge delivery system. *Current Drug Delivery* 2007;4(2):123–9.

59. Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. *International Journal of Health Sciences*, 5(2), vi-ix. <https://doi.org/10.53730/ijhs.v5n2.2937>
60. Zaki-Rizkalla, CM, Latif-Aziz, R, Soliman. In vitro and in vivo evaluation of hydroxyzine hydro ride microsponges for topical delivery. *American Association of Pharmaceutical Scientists* 2011;12(3):989–1001.
61. Bolmal UB, Manvi FV, Rajkumar K, Palla SS, Paladugu A, Reddy KR. Recent advances in nanosponges as drug delivery system. *Int J Pharm Sci Nanotechnol* 2013;6:1934-44.
62. Shivani S, Poladi KK. Nanosponges-novel emerging drug delivery system: a review. *Int J Pharm Sci Res* 2015;6:529.
63. Thakre AR, Gholse YN, Kasliwal RH. Nanosponges: a novel approach of drug delivery system. *J Med Pharm Allied Sci* 2016;78